Gelesis tables its pending, $56 million initial public offering due to 'turbulent' U.S. biotech market.
Gelesis reportedly tabled its pending, $56 million initial public offering due to the turbulence of the U.S. biotech market.
The Boston-based company said in April that would look to float 4 million shares at $12 to $14 apiece. Gelesis makes makes an anti-obesity pill using a super-absorbent hydrogel to induce feelings of satiety.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Hh9dvJ
Cap comentari:
Publica un comentari a l'entrada